As of 11-2-2018 the FDA conditionally approved Loralatinib. It’s brand name is Lorbrena.
The approval is for Loralatinib treatment for patients: 1) as a third line after crizotinib and one other ALK inhibitor (basically Brigatinib), or 2) as a second line treatment after either: A) Alectinib, or B) Ceritinib.
At this time Brigatinib has not been approved as a first line treatment by The FDA. Although a positive Phase 3 trial results were recently published.
The FDA approval is conditioned on a Phase 3 trial being completed. A description is posted on March 1, 2019 on this site.